1. Dong, Chenchen, Li, Peng, Wu, Yue, Guo, Zhong, He, Rui. . The 1q21.3 region driver gene EFNA3 promotes disease progression via inhibition of lung adenocarcinoma cell apoptosis. In Translational cancer research, 11, 1309-1320. doi:10.21037/tcr-22-979. https://pubmed.ncbi.nlm.nih.gov/35706812/
2. Husain, Abdullah, Chiu, Yung-Tuen, Sze, Karen Man-Fong, Chung, Clive Yik-Sham, Ng, Irene Oi-Lin. 2022. Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma. In Journal of hepatology, 77, 383-396. doi:10.1016/j.jhep.2022.02.018. https://pubmed.ncbi.nlm.nih.gov/35227773/
3. Zheng, Peng, Liu, XiaoLong, Li, Haiyuan, Wang, Na, Chen, Hao. 2022. EFNA3 Is a Prognostic Biomarker Correlated With Immune Cell Infiltration and Immune Checkpoints in Gastric Cancer. In Frontiers in genetics, 12, 796592. doi:10.3389/fgene.2021.796592. https://pubmed.ncbi.nlm.nih.gov/35126464/
4. Wang, Yi-Fan, Hu, Yu-Ning, Shen, Ze-Fan, Wang, Heng, Zhang, Qi. 2023. Clinicopathological and prognostic significance of Ephrin A3 in bladder urothelial carcinoma. In Oncology letters, 26, 524. doi:10.3892/ol.2023.14111. https://pubmed.ncbi.nlm.nih.gov/37927410/
5. Deng, Mingming, Tong, Run, Zhang, Zhe, Zhou, Xiaoming, Hou, Gang. 2021. EFNA3 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with lung adenocarcinoma. In Cancer cell international, 21, 535. doi:10.1186/s12935-021-02226-x. https://pubmed.ncbi.nlm.nih.gov/34645436/
6. Ye, Bozhi, Liang, Xiaohe, Zhao, Yihan, Huang, Weijian, Huang, Zhouqing. 2022. Hsa_circ_0007478 aggravates NLRP3 inflammasome activation and lipid metabolism imbalance in ox-LDL-stimulated macrophage via miR-765/EFNA3 axis. In Chemico-biological interactions, 368, 110195. doi:10.1016/j.cbi.2022.110195. https://pubmed.ncbi.nlm.nih.gov/36191606/
智鼠故事 
